John F. Crowley
Chairman of the Board, Chief Executive Officer
John F. Crowley is our Chairman and CEO. John's involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children's lives). In 2001, Novazyme was acquired by Genzyme Corporation and John continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.
John and his family have been profiled on the front page of The Wall Street Journal and are the subjects of a book by Pulitzer prize-winning journalist Geeta Anand, "The Cure: How a Father Raised $100 Million-And Bucked the Medical Establishment-In a Quest to Save His Children." The major motion picture, Extraordinary Measures, starring Brendan Fraser and Harrison Ford, is inspired by the Crowley family journey. John is the author of a personal memoir: Chasing Miracles: The Crowley Family Journey of Strength, Hope, and Joy.
John is also a commissioned officer in the U.S. Navy Reserve, assigned to the United States Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a B.S. in Foreign Service from Georgetown University, and earned a J.D. from the University of Notre Dame Law School and an M.B.A. from Harvard. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. He is the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. John is a Henry Crown Fellow at the Aspen Institute.
Bradley L. Campbell
President and Chief Operating Officer
Bradley L. Campbell is the President and Chief Operating Officer of Amicus and brings over 15 years of experience in the Orphan Drug industry. After joining in 2006, he subsequently took on roles of increasing responsibility throughout the organization. In his current capacity, Mr. Campbell leads the strategy, design and leadership of global commercial operations to support the launch of migalastat, a small molecule personalized medicine in development for the treatment of Fabry Disease. He also oversees Technical Operations, Global Marketing, and Program Management functions.
Prior to Amicus, Mr. Campbell was with Genzyme, serving first as Product Manager for Myozyme® for Pompe disease and later as Business Director of their cardiac gene therapy programs. He has also worked in sales and marketing for Bristol-Myers Squibb, and as a strategy consultant for Marakon Associates.
Mr. Campbell is active with various Boards and philanthropic organizations. He serves as a member of the Board of Directors of Progenics Pharmaceuticals, a public company developing innovative medicines and other products for targeting and treating cancer. He is a member of the BioNJ Board of Directors and is Amicus’ representative to HINJ (Health Care Initiative of New Jersey) Board of Trustees. He is a past President of the National Tay-Sachs and Allied Diseases Association Board of Directors, and currently serves on their Corporate Advisory Council. Bradley received a B.A. in Public Policy from Duke University and an M.B.A. from Harvard Business School.
Senior Vice President, Finance and Administration
Daphne Quimi joined Amicus in October 2005 and currently serves as Senior Vice President, Finance and Corporate Controller. She brings experience in public accounting and financial reporting. Prior to Amicus, Ms. Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department at Johnson & Johnson. Ms. Quimi received a B.S. in Accountancy from Monmouth University and an M.B.A from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the Institute of Management Accountants.
Senior Vice President, International
David Allsop joined Amicus in April 2015 as Senior Vice President, International. Mr. Allsop brings international General Management and commercial experience in the biopharmaceutical industry between Biogen Idec and Janssen-Cilag, with extensive operational and strategic leadership in the areas of neurology, autoimmune diseases, hemophilia, gastroenterology, dermatology, and renal. He has successfully launched three blockbuster therapies internationally as well as many other therapies both nationally and internationally. Mr. Allsop has both direct and indirect experience in securing market access and reimbursement in the European Union and international markets.
Prior to joining Amicus, Mr. Allsop was instrumental in building Biogen’s international commercial organization over the last 17 years. He most recently served as Senior Vice President, Europe and Canada, with full responsibility for the business and organization in those territories. While at Biogen he led the successful international launch of several products in the multiple sclerosis franchise, including Avonex®, Tysabri®, Fampyra®, Tecfidera® and Plegridy™ as well as taking responsibility for the hemophilia development organization. Prior to his tenure at Biogen, Mr. Allsop spent 10 years in roles of increasing responsibility at Janssen-Cilag, working in gastroenterology, dermatology and renal, including building and running a number of commercial units and taking responsibility for the Company’s largest brand in the United Kingdom.
Ellen S. Rosenberg
General Counsel and Corporate Secretary
Ellen S. Rosenberg joined Amicus Therapeutics in February of 2016 as General Counsel and Corporate Secretary. She brings legal experience in the biopharmaceutical and medical device industry including mergers and acquisitions, product launches, risk management, and compliance matters. Prior to joining Amicus, she served as Senior Vice President, Associate General Counsel of Shire Pharmaceuticals. Prior to Shire, Ms. Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD Serono Inc., the U.S. affiliate of Merck KGaA.
Ms. Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School.
Enrique Diloné Ph.D., RAC
Senior Vice President, Technical Operations
Enrique Diloné joined Amicus in August 2009 and currently serves as Senior Vice President, Technical Operations. He brings experience in drug development. Prior to joining Amicus, Dr. Diloné served as Executive Director of Quality and Analytics at NovaDel Pharma Inc., a specialty pharmaceutical company developing oral spray formulations, from February 2007 to August 2009. He served as Senior Director/Director of Analytical Operations at OSI/Eyetech Pharmaceuticals from February 2002 to December 2006. He also worked in several pharmaceutical development departments at Wyeth and Hoffmann-La Roche.
Dr. Diloné received a B.A. in Chemistry from New York University, and a Ph.D. and a M.S., both in Chemistry, from Seton Hall University. He graduated from Harvard Business School’s General Management Program in 2013, and is certified in U.S. Regulatory Affairs.
Hung Do Ph.D.
Chief Science Officer
Hung Do joined Amicus in December 2013 and currently serves as Chief Scientific Officer. Dr. Do brings experience in the field of lysosomal storage diseases (LSDs) and enzyme replacement therapies (ERTs). Prior to joining Amicus, Dr. Do was a Co-founder and Chief Scientific Officer of Callidus Biopharma, a privately-held biologics company that was acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to demonstrate proof-of-concept for ERTs, and served as the project leader for a second-generation Pompe ERT at Genzyme. Dr. Do also led molecular biology, cell culture and purification work and helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme, which was acquired by Genzyme.
Dr. Do holds a Ph.D. in medical biochemistry and genetics from Texas A&M University (mentored by Professor Arthur E. Johnson) and was a post-doctoral fellow in Hematology/Oncology at Emory University (Dr. John S. Lollar). Dr. Do utilizes his focused training in protein synthesis, folding & trafficking to develop better targeted therapeutic treatments for genetic diseases.
Jay A. Barth M.D.
Chief Medical Officer
Jay A. Barth joined Amicus Therapeutics in March 2014 as Chief Medical Officer. Dr. Barth brings experience in drug development, clinical research and medical affairs. Prior joining Amicus, Dr. Barth held roles of increasing responsibility at PTC Therapeutics, Inc. from 2009 to 2014. He most recently served as PTC’s Senior Vice President, Clinical Development. In this role he led the clinical team and oversaw all global clinical development programs, focusing on rare diseases including Duchenne Muscular Dystrophy and Cystic Fibrosis. Previously Dr. Barth served as Executive Director of Clinical Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US, Inc; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical Research Inc.
Dr. Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School of Medicine. He is a member of the American Gastroenterological Association, the American College of Gastroenterology, and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. He is also the author of numerous publications in the fields of medicine and clinical research.
Jayne C. Gershkowitz
Chief Patient Advocate
Jayne C. Gershkowitz joined Amicus in June 2006 and currently serves as Chief Patient Advocate. She is a long-time patient advocacy professional with expertise in the rare disease community, specifically in the LSD space. Prior to joining Amicus, Ms. Gershkowitz served as Executive Director at the NTSAD Association, where she co-founded the LSD Research Consortium in partnership with the National Institute of Neurological Disorders and Stroke (NINDS) and established the NTSAD Research Initiative. Her earlier career experience encompasses newspaper journalism; corporate and non-profit marketing communications; and social services.
Ms. Gershkowitz is active in several organizations within the rare disease community as well as the broader biotech arena. She is a Co-founder and Chair of the Patient Advocacy Committee of BioNJ, and Vice President of Education of the Board of Directors of the NTSAD Association. She is currently a member of the Steering Committee of the Healthcare Institute of New Jersey; the Patient Advocacy and Access and Reimbursement Committees of the Corporate Alliance of the Global Genes RARE Project; and the Policy Working Group of the National Organization for Rare Disorders Corporate Council. Ms. Gershkowitz earned a degree in journalism from the the Newhouse School of Public Communications at Syracuse University and studied business administration at the Radcliffe Graduate Seminars Program.
Jeffrey P. Castelli Ph.D.
Senior Vice President, Program Management and Portfolio Planning
Jeffrey P. Castelli joined Amicus in July 2005 and currently serves as Senior Vice President, Program Management and Portfolio Planning. He brings experience in program management, business operations, alliance management, and as a management consultant. Prior to joining Amicus, Dr. Castelli was a Manager at Health Advances LLC and previously served as a Business Development Analyst at Neose Pharmaceuticals Inc.
Dr. Castelli received a B.S. from West Chester University and a Ph.D. from the University of Pennsylvania.
Kurt J.W. Andrews
Senior Vice President, Human Resources
Kurt J.W. Andrews joined Amicus Therapeutics in February of 2016 as Senior Vice President, Human Resources. Mr. Andrew brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy, implementation of organization-wide goals and strategies, performance management, and compensation planning. Prior to joining Amicus, Mr. Andrews served as Vice President, Human Resources at Valeritas, Inc. Previously Mr. Andrews was Vice President, Human Resources and Administration at PTC Therapeutics, Inc.
Mr. Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign.
Michael Diem M.D.
Senior Vice President, Business and Corporate Development
Dr. Michael Diem joined Amicus Therapeutics in September 2017 as Senior Vice President, Business and Corporate Development. He brings many years of global experience in the pharmaceutical and biotechnology industries as well academic and clinical medicine. Prior to joining Amicus, Dr. Diem was Senior Vice President of Corporate and Business Development at Aevi Genomic Medicine, where he led all business development and licensing activities. Previously, Dr. Diem was the Global Head of Corporate Strategy and Corporate Development for AstraZeneca, where he was responsible for mergers and acquisitions, externalization opportunities and divestitures, global opportunities in new areas of business and the company’s strategic investment activities (including MedImmune Ventures). Prior to joining AstraZeneca, Dr. Diem was the Head of Business Development for GSK Rare Diseases where he led the partnerships, licensing and mergers and acquisitions activities that formed the Company’s rare disease portfolio. Earlier he was a partner in GSK’s corporate venture capital firm, SR One, Limited and served on the boards of numerous companies. Prior to GSK, Mike was an associate at Frantz Medical Ventures and practiced medicine for six years.
Dr. Diem holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School and an MBA from the Weatherhead School of Management at Case Western Reserve University. He completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program. Mike is currently a board director at VenatoRx Pharmaceuticals and is a member of the board of governors of the Boys and Girls Clubs of Philadelphia.
Patrik S. Florencio Esq.
Chief Compliance Officer
Patrik Florencio joined Amicus Therapeutics in August 2015 as Chief Compliance Officer. Prior to Amicus, Mr. Florencio was the Chief Compliance Officer of NPS Pharmaceuticals Inc. Previously he was the Chief Compliance Officer of Sandoz Inc., where he led both corporate compliance and served as corporate security for almost nine years. Prior to joining Sandoz, Mr. Florencio practiced health law at the law firm of Ropes & Gray in New York City, where he counseled pharmaceutical, hospital system, academic medical center, and other healthcare clients on a host of government enforcement, compliance, and regulatory matters.
Mr. Florencio graduated with degrees in common law, civil law, and neuroscience from McGill University in Montreal, Canada.
William D. "Chip" Baird, III
Chief Financial Officer
William D. "Chip" Baird joined Amicus Therapeutics in April 2012 as Chief Financial Officer. He brings experience in finance and strategic planning. Prior to Amicus Mr. Baird held roles of increasing responsibility for over 10 years at PTC Therapeutics, Inc. As Chief Financial Officer of PTC from April 2005 to April 2012, he was responsible for all areas of finance, investor and public relations, human resources, facilities and project management. During his tenure at PTC, he was instrumental in raising over $500 million through a combination of venture capital, non-dilutive grant funding, collaborations with industry-leading pharmaceutical and biotech companies, and debt financings. Previously, Mr. Baird worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.
Mr. Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. in finance from The Wharton School of the University of Pennsylvania.